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Abstract

Background We examined the usefulness of erythrocytebound C4d (EC4d) to monitor disease activity in SLE.
Methods Data and blood samples were collected from
three different studies, each of which included longitudinal
evaluations using the Physicians Global Assessment (PGA)
of disease activity and the Safety of Estrogens in Lupus
Erythematosus National Assessment (SELENA) SLE Disease
Activity Index (SLEDAI), which was assessed without antidouble-stranded DNA (dsDNA) and low complement C3/
C4 (clinical SELENA-SLEDAI). EC4d levels were determined
using flow cytometry; other laboratory measures included
antibodies to dsDNA, C3 and C4 proteins. Relationships
between clinical SELENA-SLEDAI, PGA and the laboratory
measures were analysed using linear mixed effect models.
Results The three studies combined enrolled 124
patients with SLE (mean age 42 years, 97% women, 31%
Caucasians and 34% African-Americans) followed for an
average of 5 consecutive visits (range 2–13 visits). EC4d
levels and low C3/C4 status were significantly associated
the clinical SELENA-SLEDAI or PGA in each of the three
study groups (p<0.05). Multivariate analysis revealed that
EC4d levels (estimate=0.94±0.28) and low complement
C3/C4 (estimate=1.24±0.43) were both independently and
significantly associated with the clinical SELENA-SLEDAI
(p<0.01) and PGA. EC4d levels were also associated with
the clinical SELENA-SLEDAI (estimate: 1.20±0.29) and PGA
(estimate=0.19±0.04) among patients with chronically low
or normal C3/C4 (p<0.01). Anti-dsDNA titres were generally
associated with disease activity.
Conclusion These data support the association of EC4d
with disease activity regardless of complement C3/
C4 status and its usefulness in monitoring SLE disease.
Additional studies will be required to support these
validation data.

Introduction
SLE is an autoimmune disease characterised
by autoantibodies to self-antigens (such as
double-stranded DNA (dsDNA)) and formation of immune complexes that activate the
complement system to generate inflammatory
anaphylatoxins resulting in organ damage.1
Anti-dsDNA antibodies and low complement C3 or C4 (C3/C4) have established
clinical utility in the routine monitoring of

SLE, and these laboratory measures have
been incorporated in clinical research instruments such as the SLE Disease Activity Index
(SLEDAI) for over two decades2 and in SLE
classification criteria.3 However, C3 and C4
are acute phase reactant proteins, and using
their levels to monitor SLE can be unreliable because their hyperconsumption during
the active phase of disease can be offset by
inflammation and compensatory hepatic
synthesis.4 Moreover, C4 levels are dependent
on copy number variations in C4A and C4B
and thus can be constitutively low, irrespective
of disease status.4 Anti-dsDNA is a very useful
marker but is limited by its low sensitivity
for SLE and performance as a stand-alone
marker.5 It follows that additional laboratory
measures of disease activity could be of value,
not only to improve disease monitoring and
treatment optimisation but also to improve
outcome measures for therapeutic trial
interventions.
In the past decades, complement pathway
activation has been assessed using soluble
split fragments,6 7 anaphylatoxins8 9 or stable
C4d-bound complement activation products on erythrocytes (EC4d),10–13 and these
laboratory measures represent additional
approaches to assessing disease in SLE. We
recently reported that EC4d was linked to
clinical improvement in patients selected for
active disease and complement activation. We
also established the role of anti-C1q antibody
titres in the monitoring of SLE renal disease.11
In this study, we compare the performance of
EC4d, low complement C3/C4, and autoantibodies to dsDNA and C1q in tracking disease
activity. For this, we combined data and laboratory findings from our original study11 with
two additional cohorts with the objective of
evaluating the generalisability of our previous
findings.
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Table 1 Patient characteristics at baseline
Study group 1

Study group 2

Study group 3

Study groups 1–3

Number of patients
Age

37
34±2

64
42±1

23
56±3

124
42±1

Gender (% of women)

95

97

100

97

Study visit per subject, average± SEM, median
(range)

10.5±0.6, 387
(2–3)

2.0±0, 129
(2–3)

4.7±0.2, 108
(3–7)

5.0±0.4, 624
(2–13)

 Caucasians (%)

14

34

52

31

 African-Americans (%)

24

36

43

34

 Hispanics (%)

35

13

0

17

 Asians (%)

22

8

0

10

 Others (%)

5

9

4

7

 Average±SEM

1.6±0.1

1.4±0.1

0.6±0.1

1.3±0.1

 Median (range)

1.6 (0.2–2.8)

1.2 (0.6–2.6)

0.5 (0.0– 2.0)

1.3 (0.0– 2.8)

 Average±SEM

8.1 ± 0.8

6.3±0.1

1.4±0.1

6.0±0.4

 Median, range

8.0 (2–25)

6.0 (2-17)

2.0 (0–4)

5.0 (0–25)

 ANA titres (≥1:80)

96%

80%

76%

86%

 Anti-dsDNA (units; %>35 units)

615±180; 91

74±18; 38

14±1; 4

211±55;46

 Anti-C1q (units; %>20 units)

58±11; 62

14±2; 20

8±2; 13

26%±4; 31

 EC4d (net MFI; %>14 net MFI)

51±19; 86

20±3; 39

14±6; 14

28±6; 49

 Low C3 or C4 (%)

73

39

22

46

 Prednisone (%; dose (mg/day))

47; 22.8±4.8

9; 16.0±2.9

26; 5.0±0.0

24; 17.8±3.2

 Hydroxychloroquine (%)

58

75

100

75

 Azathioprine (%)

11

0

0

5

 Methotrexate (%)

8

3

100

24

 Mycophenolate (%)
 Belimumab (%)

33
8

23
2

0
0

21
3

Ethnicities

PGA (0–3 cm)

Clinical SELENA-SLEDAI

Antibody measures

Complement measures

Treatment information

Results are expressed as average, SEM and median (range) as appropriate.
dsDNA, double-stranded DNA; EC4d, erythrocyte-bound C4d; MFI, mean fluorescence intensity; PGA, Physicians Global Assessment;
SELENA-SLEDAI, Safety of Estrogens in Lupus Erythematosus National Assessment—SLE Disease Activity Index.

Methods
All patients provided informed consent and participated
in institutional-approved protocols that allowed the use
of their samples and clinical data. The objective of each
of the three studies was to evaluate the relationships
between laboratory and disease activity measures. All
patients fulfilled the 1982 American College of Rheumatology (ACR) criteria revised in 1997. The first study
group (study group 1) has been reported11 and enrolled
37 patients at four sites, with all patients with SLE selected
for active disease and requiring complement activation as
defined by abnormal EC4d or B-lymphocyte C4d levels
(>99th percentile of healthy controls). The two additional
study groups we report (study group 2 and 3) enrolled
2

64 and 23 consecutive SLE, respectively, all coming
from two academic lupus centres in the USA (Oklahoma Medical Research Foundation and Johns Hopkins
University School of Medicine, respectively). Study group
2 included patients with SLE with a range of activity and
treatment. All patients from the third study group were
treated with methotrexate and hydroxychloroquine, and
none presented with renal disease (>0.5 g urine protein).
In each study group, the relationships between the laboratory measures and disease activity were assessed longitudinally by the Physician’s Global Assessment (PGA) on a
0–3-point Visual Analogue Scale as well as by the clinical
Safety of Estrogens in Lupus Erythematosus National
Assessment (SELENA) SLE Disease Activity Index
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variables and complement (low C3/C4, EC4d) and antibodies (anti-dsDNA (Quanta Flash) or anti-C1q titres)
measures as independent predictors. Autoantibody and
EC4d levels were log normalised for the analysis. Marginal
R2 was calculated for each marker to evaluate the proportion (%) of variance explained by the independent
predictors, and multivariate analyses were conducted.
Mann-Whitney test was used to compare groups.

Figure 1 Complement and antibody abnormalities at
baseline and relation to disease activity clinical SELENASLEDAI (A) and PGA scores (B) in relation to the presence
or absence of low complement (C3/C4), abnormal EC4d
(>14 net MFI), anti-dsDNA (>35 units) and anti-C1q (>20
units) levels. Results are presented as average (SEM).
The presence of these abnormalities was associated with
higher clinical SELENA-SLEDAI and PGA (p<0.01). dsDNA,
double-stranded DNA; EC4d, erythrocyte-bound C4d;
MFI, mean fluorescence intensity; PGA, Physicians Global
Assessment; SELENA-SLEDAI, Safety of Estrogens in Lupus
Erythematosus National Assessment—SLE Disease Activity
Index.

SELENA-SLEDAI (2), which was scored without the antidsDNA and complement components. An additional
modification (known as the hybrid SELENA-SLEDAI)
was that proteinuria was scored as positive in the presence of >0.5 g/24 hours urine protein, if attributed to SLE
renal disease, but irrespective of a change from a previous
visit (SLEDAI 2K definition for proteinuria).14
At each study visit, whole blood was collected in EDTA
tubes and routed to the reference clinical laboratory at
Exagen Diagnostics within 48 hours. EC4d levels were
measured on receipt using quantitative flow cytometry
as described previously15 and expressed as net mean
fluorescence intensity (MFI). Antibody titres to dsDNA
(Quanta Flash) and C1q (INOVA Diagnostics, San Diego,
California, USA) were determined using immunoassays.
The low complement (C3 or C4) status was determined
using serum C3 and C4 levels measured at each of the
study sites. Site investigators were blinded to EC4d, antidsDNA titres (Quanta Flash) and anti-C1q assay results
during each study. Low complement C3/C4 and antidsDNA status (as determined at each of the study sites)
were available to all evaluators.
The three study groups were analysed separately and in
combination. Relationships between SLE disease activity
and laboratory measures were analysed using linear
mixed effect models (random intercept and fixed slope)
with the clinical SELENA-SLEDAI and PGA as dependent

Results
Baseline characteristics of the population are presented
in table 1 and in online supplementary tables I and II).
Six hundred and twenty-four study visits were completed
among the 124 enrolled patients. All patients had at least
one follow-up visit after a baseline assessment, with a
mean of 5 visits per patient. At baseline, patients enrolled
in study group 1 (the active disease study group) had
higher clinical SELENA-SLEDAI (median eight points)
than those enrolled in study groups 2 and 3 (median
6 and 2 points, respectively) (p<0.01). The combined
dataset (study groups 1–3; n=124 patients) provided a
wider range of patients from well controlled to clinically
active disease. Patients with abnormal complement and
antibody titres had higher clinical disease activity than
those with normal values (figure 1).
The linear mixed model estimating the relationships
between disease activity (by clinical SELENA-SLEDAI or
PGA) and laboratory measures are presented in table 2.
EC4d levels were significantly associated with the clinical SELENA-SLEDAI in all three study groups (p<0.042,
marginal R2 range 2.0% to 10.7%), while low C3/C4 status
only reached significance with this outcome measure in
study group 1, which had been selected for complement
activation (p=0.005, marginal R2=2.7%). EC4d levels were
also significantly associated with the PGA in study groups
1 and 2 (p<0.05, marginal R2=2.2% and 8.7%, respectively) but was not significant in study group 3 (p=0.363,
marginal R2=1.4%), which had much lower disease
activity overall at baseline. Low C3/C4 status correlated
significantly with PGA in all three study groups (p<0.01,
marginal R2 range 4.0% to 9.1%). Altogether, EC4d and
low C3/C4 status were both associated with at least one of
the two disease activity measures in all study groups. AntidsDNA by Quanta Flash and anti-C1q titres was also associated with disease activity (table 2). However, in contrast
to anti-dsDNA, anti-C1q was not associated with disease
activity in the third study group of patients with SLE, all
with non-renal disease and treated with methotrexate and
hydroxychloroquine.
When the three study groups were combined, univariate analysis revealed that EC4d, low C3/C4 and antidsDNA levels were associated with disease activity by
PGA and clinical SELENA-SLEDAI (table 2). Abnormal
EC4d (>14 net MFI) was associated with clinical SELENA-SLEDAI (estimate=1.29±0.39; R2=2.2%; p<0.01)
and PGA (estimate=0.11±0.06; R2=0.8%; p=0.05), and
a total of 37 SLE (31%) changed their EC4d status
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Table 2 Linear mixed model estimates for the clinical SELENA-SLEDAI and PGA in relation to laboratory measures
Subject/
Study group visit, n

Slope
Intercept (SE) estimate (SE) P values

Marginal
R2 (%)

Marker

Outcome

EC4d
(log net MFI)

Clinical SELENA- 1
SLEDAI
2

37/384
64/126

2.52±1.55
1.81±1.05

0.94±0.46
1.36±0.40

0.042
0.001

2.0
10.3

3

23/102

0.09±0.57

0.74±0.25

0.005

10.7

124/612

1.49±0.76

1.17±0.27*

<0.001

5.7

37/385

0.77±0.20

0.12±0.06

0.047

2.2

1–3
PGA

1
2

64/128

0.75±0.15

0.18±0.06

0.002

8.7

3

23/106

0.50±0.24

0.10±0.11

0.363

1.4

124/619

0.64±0.11

0.17±0.04

<0.001

5.6

1–3
Low complement Clinical SELENA- 1
C3/C4
SLEDAI
2

37/383

4.32±0.73

1.72±0.61

0.005

2.7

64/127

4.65±0.46

1.46±0.74

0.052

3.6

3

23/103

1.47±0.28

0.71±0.48

0.148

2.8

124/613

3.80±0.35

1.68±0.42†

<0.001

3.7

37/384

0.99±0.08

0.26±0.08

0.002

4.0

1–3
PGA

1
2

64/127

1.11±0.06

0.27±0.10

0.010

5.7

3

23/107

0.58±0.11

0.47±0.17

0.007

9.1

124/618

0.95±0.05

0.31±0.06

<0.001

5.9

37/379

−1.11±1.43

1.27±0.26

<0.001

17.4

64/126

2.03±1.03

0.97±0.30

0.002

9.7

1–3
Anti-dsDNA
(log net MFI)

Clinical SELENA- 1
SLEDAI
2
3
1–3
PGA

1

1.01±0.55

0.070

4.6

0.44±0.65

1.08±0.15

<0.001

18.2

37/380

0.69±0.17

0.09±0.03

0.005

5.9

2

64/128

0.83±0.15

0.11±0.04

0.009

6.3

23/106

−0.52±0.52

0.47±0.20

0.019

7.6

124/614

0.68±0.09

0.10±0.02

<0.001

8.3

37/383

1.50±1.18

1.27±0.32

<0.001

6.6

64/126

2.38±0.98

1.28±0.42

0.003

8.3

Clinical SELENA- 1
SLEDAI
2
3

23/102

1.08±0.57

0.34±0.30

0.265

2.1

124/611

1.55±0.60

1.24±0.22

<0.001

9.9

1

37/384

0.62±0.14

0.17±0.04

<0.001

8.5

2

64/128

0.91±0.14

0.13±0.06

0.029

4.3

23/106
124/618

0.76±0.24
0.70±0.09

−0.04±0.12
0.15±0.03

0.765
<0.001

0.2
7.5

1–3
PGA

−0.94±1.44

3
1–3
Anti-C1q
(log net MFI)

23/102
124/607

3
1–3

Intercept, slope estimates, p values and marginal R2 are given.
*One log EC4d levels were associated with a 1.2-point in clinical SELENA-SLEDAI.
†Low C3/C4 status was associated with a 1.7-point clinical SELENA-SLEDAI.
dsDNA, double-stranded DNA; EC4d, erythrocyte-bound C4d; MFI, mean fluorescence intensity; PGA, Physicians Global Assessment;
SELENA-SLEDAI, Safety of Estrogens in Lupus Erythematosus National Assessment—SLE Disease Activity Index.

from baseline during at least one follow-up visits (of
those, 8 subjects changed their status from normal
EC4d at baseline to abnormal EC4d at follow-up).
Multivariate analysis also revealed that EC4d levels
and low complement C3/C4 were both independently
and significantly (p<0.01) associated with the clinical
SELENA-SLEDAI and PGA score (table 3), and adding
EC4d to low complement C3/C4 resulted in a higher
proportion of variance explained (R2=7.7% for clinical
SELENA-SLEDAI) by comparison to low C3/C4 alone
4

(3.7%, table 2), thus suggesting the additional information gained from EC4d.
Of the 124 patients studied, 97 presented with either
chronically low C3/C4 (n=40, followed for 9.2±0.3 visits) or
normal C3/C4 at all visits (n=57, followed for 5.4±0.3 visits).
In this subset (including 401 study visits), a one log EC4d
level was associated with a 1.2-point increase in the SELENA-SLEDAI and a 0.19-point increase in PGA, supporting
the value of EC4d when there are invariant levels of classical
complement proteins (table 4).
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Table 3 Linear mixed model estimates for the clinical SELENA-SLEDAI and PGA in relation to laboratory measures by
multivariate analysis
Model

Outcome variable

Predictors

Slope estimate; p values

EC4d + low C3/C4

Clinical
SELENA-SLEDAI

Intercept
EC4d (log net MFI)+

1.53±0.75;
0.94±0.28; p<0.01*

Low complement C3/C4

1.24±0.43; p<0.01

Intercept

0.64±0.10;

EC4d (log net MFI)+

0.12±0.04; p< 0.01

Low complement C3/C4

0.24±0.06; p<0.01

Intercept

−0.53±0.12;

EC4d (log net MFI)+

0.49±0.28; p=0.07

Low complement C3/C4+

0.79±0.43; p=0.07

Anti-dsDNA (log net MFI)

0.90±0.17; p=0.01

Intercept

0.52±0.12;

EC4d (log net MFI)+

0.09±0.04; p = 0.03

Low complement C3/C4+
Anti-dsDNA (log net MFI)

0.20±0.06; p< 0.01
0.06±0.02; p = 0.01

PGA

EC4d
+ low C3/C4 +antidsDNA

Clinical SELENASLEDAI

PGA

Marginal
R2 (%)
7.7

9.1

19.6

12.3

Intercept, slope estimates, p values and marginal R2 are given.
*One log EC4d levels and low complement C3/C4 were associated with a 0.9-point and 1.2-point in clinical SELENA-SLEDAI, respectively;
presence of both one log EC4d levels and low complement C3/C4 was associated with 2.1-point clinical SELENA-SLEDAI.
dsDNA, double-stranded DNA; EC4d, erythrocyte- bound C4d; MFI, mean fluorescence intensity; PGA, Physicians Global Assessment;
SELENA-SLEDAI, Safety of Estrogens in Lupus Erythematosus National Assessment— SLE Disease Activity Index.

Discussion
In this report, we have analysed the relationships between
laboratory measures and disease activity in three study
groups. The findings from the first study group have been
reported previously, and all patients with SLE from this
group were selected for active disease in the presence of
abnormal complement activation.11 The two additional
studies reported here, all designed to evaluate complement components in relation to SLE disease activity, add
to the growing body of evidence that quantitative flow
cytometry determination of C4d split products on erythrocytes may be useful in the monitoring of SLE.
We analysed the data separately by study groups and in
combination. While EC4d levels were independently associated with clinical SELENA-SLEDAI in all three study
groups, the association with disease measured by PGA
did not reach significance in the third study group, which
had the lowest disease activity. Low complement C3/C4
was associated with disease measured by PGA in all study
groups but did not reach significance with the clinical
SELENA-SLEDAI in the third study group. The precise
reasons for the inconsistencies between laboratory and
clinical activity measures are unclear; nevertheless, both
complement components were significantly associated
with at least one of the two clinical measures in each of
the study groups, thus suggesting that both EC4d and low
complement C3/C4 are useful laboratory measures.
As expected, when we combined the three study
groups, univariate analysis indicated that EC4d and low
complement remained associated with disease activity

irrespective of clinical activity measure. Multivariate
analysis also revealed that adding EC4d to low complement C3/C4 resulted in a higher proportion of variance
explained (R2=8% for clinical SELENA-SLEDAI) by
comparison to low C3/C4 alone (4%), thus suggesting
the additional information gained from EC4d.
There are potential advantages to the use of the
combined measures of complement. First, the presence
of normal complement component measures in the
absence of the complement activation product could
provide greater confidence that disease control has been
achieved. To the contrary, higher clinical disease activity
with low complement C3/C4 in the presence of complement activation products may reflect more active disease,
suggesting that therapeutic intervention may be necessary. Our analysis also indicated that in the large subset of
patients with chronically low or normal complement C3/
C4 levels, EC4d levels remained associated with disease
activity, thus supporting the potential of the laboratory
measure when C3/C4 status is not a reliable marker of
disease activity.
Abnormalities in anti-dsDNA and anti-C1q titres were
also correlates of disease activity, although anti-C1q did not
correlate with disease activity in the group of patients with
low disease activity. This most likely is due to the lack of
renal involvement in that group of patients who, for the
most part, were receiving methotrexate and hydroxychloroquine to control rash and arthritis. In contrast, as seen
above with EC4d, anti-dsDNA was associated with disease
activity in all three study groups, and thus may have value in
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Table 4 Linear mixed effect models for the clinical SELENA-SLEDAI and PGA in the presence of chronically low or normal C3/
C4 or fluctuating C3/C4
Outcome
variable
EC4d
(log net MFI)

Clinical
Low
SELENA-SLEDAI Normal

PGA

Anti-dsDNA
(log titres)

Slope
(SE)

P value

Marginal
R2 (%)

3.48±1.50
0.47±0.97

0.77±0.46
1.55±0.44

0.097
<0.001

2.6
9.0

Low or normal

97/401

1.60±0.79

1.20±0.29

<0.001

7.9

Fluctuating

27/211

0.17±1.98

1.38±0.60

0.022

3.8

Low

40/210

0.79±0.20

0.15±0.06

0.018

5.3

Normal

57/197

0.50±0.18

0.22±0.08

0.009

5.2

Low or normal

97/407

0.59±0.12

0.19±0.04

<0.001

8.7

Fluctuating

27/212

0.70±0.27

0.13±0.08

0.128

1.9

40/207

0.32±1.28

1.16±0.25

<0.001

20.0

57/190

2.55±1.00

0.40±0.33

0.228

2.0

Low or normal

97/397

0.90±0.66

1.00±0.016

<0.001

20.8

Fluctuating

27/210

−1.78±1.78

1.47±0.039

<0.001

18.9

Low

40/209

0.76±0.18

0.10±0.03

0.004

8.4

Normal

57/194

0.59±0.17

0.12±0.06

0.032

5.5

Low or normal

97/403

0.66±0.10

0.11±0.02

<0.001

12.3

Fluctuating

27/212

0.79±0.22

1.07±0.05

0.152

2.8

40/207

2.57±1.34

1.02±0.38

0.008

5.4

57/192

1.89±0.79

1.02±0.40

0.013

7.1

Clinical
Low
SELENA-SLEDAI Normal

PGA

Intercept
n/study visits (SE)
40/208
57/193

Clinical
Low
SELENA-SLEDAI Normal

PGA

Anti-C1q
(log titres)

C3/C4
status

Low or normal

97/399

1.93±0.64

1.12±0.24

<0.001

10.8

Fluctuating

27/212

0.41±1.38

1.56±0.45

<0.001

8.7

Low

40/209

0.67±0.18

0.18±0.05

<0.001

9.5

Normal

57/196

0.77±0.14

0.10±0.07

0.180

2.1

Low or normal
Fluctuating

97/405
27/213

0.67±0.10
0.78±0.18

0.17±0.03
0.12±0.06

<0.001
0.055

10.8
3.1

Intercept, slope estimates (SE) and p value with marginal R2 are given. Of the 124 patients studied, 97 presented with either chronically low
C3/C4 (n=40, followed for 9.2±0.3 visits) or normal C3/C4 at all visits (n=57, followed for 5.4±0.3 visits) and 27 presented with fluctuating C3/
C4 (followed for 10.4±0.3 visits).
dsDNA, double-stranded DNA; EC4d, erythrocyte-bound C4d; MFI, mean fluorescence intensity; PGA, Physicians Global Assessment;
SELENA-SLEDAI, Safety of Estrogens in Lupus Erythematosus National Assessment— SLE Disease Activity Index.

the monitoring of SLE in a broader group of patients with
SLE, irrespective of clinical patterns and organ involvement.
In conclusion, our data expand initial work associating
EC4d with SLE disease activity,12 and further support the
usefulness of EC4d in the monitoring of SLE. Moving
forward, it will be important to further evaluate these laboratory measures as objective endpoints in interventional
clinical trials and as aids to guide optimal treatment decisions when clinical disease activity assessment is not easily
discerned.
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